Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Isn't that how to make a killing? Maybe get a cash advance on the ol credit card?
LOLOL
GW
Nay on Brig selling.........................
I haven't bought mine yet, after which I will change to the affirmative! lol
GW
Immunomedics, Inc. (Nasdaq: IMMU) today announced the results of preclinical studies involving bispecific antibody pretargeting for radioimmunotherapy of cancer presented at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics being held in Boston, MA.
Pretargeting radioimmunotherapy, which is being pursued by IBC Pharmaceuticals, Inc., a subsidiary of Immunomedics, involves the rapid delivery of therapeutic isotopes to tumors with significantly reduced targeting to normal tissues. In the studies reported by scientists from Immunomedics, IBC Pharmaceuticals, and the Center for Molecular Medicine and Immunology, new humanized, bispecific antibodies, where one binding arm targets the carcinoembryonic antigen (CEA) expressed by a human colon cancer growing in mice and the other binding arm recognizes a peptide carrier bearing a therapeutic radioisotope, were studied in this preclinical model. The CEA- binding arm was either monovalent (single binding) or bivalent (double- binding), in order to assess the impact of differently engineered antibodies on affinity. After targeting the tumor with the bispecific antibody, followed by a delay that allows non-targeted antibody to be excreted, the therapeutic attached to the peptide is injected where it localizes selectively to the antibody bound to tumor cells.
In comparison to anti-CEA antibodies directly conjugated with an isotope, the bispecific, multivalent antibodies showed a significantly higher delivery of radiotherapeutic doses to the tumor, with a 3-fold dose-rate increase, showing also that a double-CEA binding (bivalent) arm was better than a single (monovalent) one. The results suggest that the method of bispecific antibody pretargeting should be more effective for cancer radioimmunotherapy than conventionally labeled antibodies.
"Scientists at IBC Pharmaceuticals and Immunomedics have advanced the development of this new 2-step system for improved targeting of therapeutic isotopes and, potentially, also drugs," commented Immunomedics' President and Chief Executive Officer, Cynthia L. Sullivan. "Validation of the potential for this new technology not only comes from such preclinical studies involving human tumors grafted in mice, but also from ongoing Phase I/II clinical trials in Europe involving our bispecific antibodies and pretargeting methods in patients with intestinal and medullary thyroid cancers, the results of which have been presented at medical conferences and in medical journals," Ms. Sullivan also remarked. She also mentioned that "this technology is the basis of a research collaboration just beginning between IBC Pharmaceuticals, Immunomedics, and Schering A.G. in Berlin."
NRCNA, Holiday and cold season good for Northland sales.
Grumps
Patsy, lol, we've been looking too. Trying to wait 9-12 mos. Becoming hard to resist though. Will also have to rearrange.
GW
NRCNA had nice earnings report last night. 10x avg vol today.
GW
NRCNA now 10x avg vol. (8^)
GW
NRCNA 6x avg vol. Good earning report. Just off 52 week low
GW
NRCNA....
Northland Cranberries, Inc. (OTC Bulletin Board: NRCNA), manufacturer of Northland brand 100% juice cranberry blends and Seneca brand fruit juice products, today reported fiscal 2003 year-end and fourth-quarter financial results for the periods ended August 31, 2003.
For the year ended August 31, 2003, Northland reported net earnings of $6.6 million, or $0.06 per diluted share, on net revenues of $96.5 million. That compares with net income of $53.8 million on net revenues of $101.5 million for the year ended August 31, 2002. Net income in fiscal 2002 included a net gain on forgiveness of indebtedness of $50.5 million (net of $32.8 million in taxes), or $0.64 per diluted share, resulting from the company's financial restructuring which closed on November 6, 2001.
For the fourth quarter ended August 31, 2003, Northland reported net income of $4.0 million, or $0.04 per diluted share, on net revenues of $27.2 million. That compares with a net loss of ($44,000), or zero cents per diluted share, on net revenues of $23.0 million in the fourth quarter of fiscal 2002.
Northland significantly improved its balance sheet during fiscal 2003 by reducing total liabilities by $32.8 million. The reduction in total liabilities was attributable, among other things, to improved operating cash flows and a significant decrease in debt funded primarily by cash from the settlement of litigation with Cliffstar Corporation relating to the sale of Northland's private label juice business in March 2000.
The Northland brand achieved a market share of 5.6 percent for the 12-week period ended September 7, 2003, compared to a market share of 5.1 percent for the 12-week period ended September 8, 2002. As of September 7, 2003, Northland 100% Juice Cranberry Blends were available in supermarkets nationwide that account for approximately 68.6% of total grocery sales in the United States, compared to 61.3% as of September 8, 2002.
John Swendrowski, Northland's Chairman and Chief Executive Officer, said, "We are pleased with the fiscal 2003 financial results, which represent our first full fiscal year of operations since our financial restructuring in November 2001." Swendrowski said, "Our 6.7 percent market share for the four- week period ending November 2, 2003, is also encouraging. We continue to grow our business profitably, having used approximately 786,000 barrels (78.6 million pounds) of cranberries during fiscal 2003."
Northland also announced that it has retained Stephens Inc. of Little Rock, Arkansas, to serve as its financial advisor and assist the company in evaluating various strategic alternatives, including, without limitation, potential acquisitions, mergers, joint ventures, licensing arrangements or investments in Northland, a potential sale of the company, as well as remaining an independent public company.
"Given the improvement in our financial condition since our financial restructuring, we believe the time is right to explore various strategic alternatives in an effort to maximize shareholder value," Swendrowski said. "We are excited about the opportunity to work with Stephens to evaluate the means through which we can build on our performance and continue to grow the Northland brand."
Northland is a vertically integrated grower, handler, processor and marketer of cranberries and value-added cranberry products. The company processes and sells Northland brand 100% juice cranberry blends, Seneca brand juice products, Northland brand fresh cranberries and other cranberry products through retail supermarkets and other distribution channels. Northland also sells cranberry and other fruit concentrates to industrial customers who manufacture juice products. Northland is the only publicly-owned, regularly- traded cranberry company in the United States, with shares traded on the Over- the-Counter Bulletin Board under the listing symbol NRCNA.
NRCNA.....
Northland Cranberries, Inc. (OTC Bulletin Board: NRCNA), manufacturer of Northland brand 100% juice cranberry blends and Seneca brand fruit juice products, today reported fiscal 2003 year-end and fourth-quarter financial results for the periods ended August 31, 2003.
For the year ended August 31, 2003, Northland reported net earnings of $6.6 million, or $0.06 per diluted share, on net revenues of $96.5 million. That compares with net income of $53.8 million on net revenues of $101.5 million for the year ended August 31, 2002. Net income in fiscal 2002 included a net gain on forgiveness of indebtedness of $50.5 million (net of $32.8 million in taxes), or $0.64 per diluted share, resulting from the company's financial restructuring which closed on November 6, 2001.
For the fourth quarter ended August 31, 2003, Northland reported net income of $4.0 million, or $0.04 per diluted share, on net revenues of $27.2 million. That compares with a net loss of ($44,000), or zero cents per diluted share, on net revenues of $23.0 million in the fourth quarter of fiscal 2002.
Northland significantly improved its balance sheet during fiscal 2003 by reducing total liabilities by $32.8 million. The reduction in total liabilities was attributable, among other things, to improved operating cash flows and a significant decrease in debt funded primarily by cash from the settlement of litigation with Cliffstar Corporation relating to the sale of Northland's private label juice business in March 2000.
The Northland brand achieved a market share of 5.6 percent for the 12-week period ended September 7, 2003, compared to a market share of 5.1 percent for the 12-week period ended September 8, 2002. As of September 7, 2003, Northland 100% Juice Cranberry Blends were available in supermarkets nationwide that account for approximately 68.6% of total grocery sales in the United States, compared to 61.3% as of September 8, 2002.
John Swendrowski, Northland's Chairman and Chief Executive Officer, said, "We are pleased with the fiscal 2003 financial results, which represent our first full fiscal year of operations since our financial restructuring in November 2001." Swendrowski said, "Our 6.7 percent market share for the four- week period ending November 2, 2003, is also encouraging. We continue to grow our business profitably, having used approximately 786,000 barrels (78.6 million pounds) of cranberries during fiscal 2003."
Northland also announced that it has retained Stephens Inc. of Little Rock, Arkansas, to serve as its financial advisor and assist the company in evaluating various strategic alternatives, including, without limitation, potential acquisitions, mergers, joint ventures, licensing arrangements or investments in Northland, a potential sale of the company, as well as remaining an independent public company.
"Given the improvement in our financial condition since our financial restructuring, we believe the time is right to explore various strategic alternatives in an effort to maximize shareholder value," Swendrowski said. "We are excited about the opportunity to work with Stephens to evaluate the means through which we can build on our performance and continue to grow the Northland brand."
Northland is a vertically integrated grower, handler, processor and marketer of cranberries and value-added cranberry products. The company processes and sells Northland brand 100% juice cranberry blends, Seneca brand juice products, Northland brand fresh cranberries and other cranberry products through retail supermarkets and other distribution channels. Northland also sells cranberry and other fruit concentrates to industrial customers who manufacture juice products. Northland is the only publicly-owned, regularly- traded cranberry company in the United States, with shares traded on the Over- the-Counter Bulletin Board under the listing symbol NRCNA.
TVOG closed @ HOD
GW
TVOG, any opinions? Nice vol today
GW
ALTH just had somemore good news. Just hit
GW
ALT, looks like a reversal here. IMO
ALTH had good news yesterday also
GW
GONT, yup pushin to .04.
GW
CLHB a monster
CLHB had good earnings, nice turnaround story. Short positions approx 25%. Can you say Squeeeeeeeeeze!
GW
CLHB good earnings, large short position approx 25%. Should be fun. In TFSM also lisp.
GW
Hey Buzz, did you get a call from DIO about supporting the board for the upcoming vote? lol I just did, but I already sold at .42. She said I could still vote, but it's already in file 13. Are they anticipating that the shareholders will not go along with the board?
GW
GOAM..I can't believe I just flipped it this morning. Ugh!!!!!
GW
FTUS breaks 2.24 it's off to ? 2.50? 2.75?
GW
CLHB any comments?
GW
LSBC can't believe I sold for a small loss about a month ago. lol
GW
PCLE have a pos. Looking for 7.50-8.00
FTUS FWIW last year they really started taking off the 2nd week of Nov if I'm not mistaking.
GW
FTUS, I'm holding the line so far due to the positive outlook given yesterday even though they had a rough Oct. I will buy on any dip under 2.
GW
Ameritrade, as a matter of fact I had all cash deployed and used DTBP to flip GOAM this am. However if I would have chosen to hold until tomorrow or Fri I could have from past experiences.
GW
Buzz. Then I must be falling under the radar. I have had all cash balance deployed with daytrading buying power $ from broker and bought sub 1.00 (even BB) stocks and even held for a day or two.
GW
Buzz, wouldn't those maintanence calls be more based upon the % that a security drops than the $5.00 PPS? A large % drop would more effect the margin acct based upon whether their is sufficient buying power to meet required maint. I buy otc on margin so the 5.00 has not effected me at all. However it does take a higher amount of available maint to buy those low PPS stocks.
GW
PMACA, did get a nice flip on it today. Also looking for 4.50 or a smidge lower. Thanks to monk for the heads up.
GW
PMACA,ADMT, FTUS (8^)
GW
DBBD, nice call on that one. Didn't play but watched it.
GW
CIO, yes watching myself. Also LFP above avg vol just up a penny. Any feel for DYX? Plus EAG I think pulls back hard tomorrow without news.
GW
Cause were so contrary I guess lol. Keep up the great picks.
GW
FTUS...Have a feeling it's headed ^ very soon.
GW
Buzz, great calls on both!
GW
Diomed Announces Record Third Quarter Revenue up 22% and YTD 2003 Revenue up 63%
YTD 2003 Revenue from EVLT(R) Procedure Kits Increases 300%
ANDOVER, Mass., Nov 4, 2003 (BUSINESS WIRE) --
Diomed Holdings, Inc. (AMEX: DIO), a leading developer and marketer of minimal and micro-invasive medical technologies, today announced 2003 financial results for the third quarter ended September 30, 2003.
For the quarter ended September 30, 2003, Diomed Holdings, Inc. delivered revenue of $2.4 million, a 22% increase over $1.9 million in the prior year. Revenue for the nine-month period ended September 30, 2003, totaled $6.6 million, an increase of 63% or $2.6 million from the same period in 2002. Importantly, revenue from EVLT(R) procedure kits increased 59% from the first quarter run rate and four times the prior year third quarter level.
James Wylie, President and Chief Executive Officer of Diomed Holdings, Inc. commented, "Diomed delivered strong financial results, and since going public, delivered record third quarter revenue, record gross margins, and record revenue from EVLT procedure kits. From a strategic standpoint, the EVLT kit revenue growth and its recurring revenue stream is key to our business model and driving Diomed to become a significant participant in the growing market for minimal and micro-invasive medical technologies."
Gross profit for the quarter ended September 30, 2003, at $832,000, an increase of $173,000 from the same period in 2002. For the nine-month period ended September 30, 2003, the Company delivered gross profit of $2.4 million, compared to $590,000 for the same period in 2002. On a percentage basis, gross margin increased from 14% to 37% during the comparable prior year nine-month period. This increase was driven primarily by increased EVLT revenue and resulting fixed manufacturing cost leverage.
EAG CC very nice so far.
GW
billy, I just have a feeling this is just starting and has a "monk" multi bagger possibility.
GW
EAG...With the news I am now thinking close of .80 or better, with 1.00+ sometime Wed. This is pretty big for this small co. IMO only, just tired of leaving lots of $$ on the table. lol
GW